| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:16 | Breaking News: "Königs-Exosomen" senken Entzündungslevel um 90%… | bullVestor | |||
| 04:06 | Telix Reports Positive Phase 3 Results For Illuccix Prostate Cancer Imaging Trial In China | 345 | AFX News | CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announced positive top-line results from its Phase 3 registration study of TLX591-CDx (Illuccix, Kit for the preparation of 68Ga-PSMA-11)... ► Artikel lesen | |
| 11:10 | Abivax: Kommt es zur Übernahmeschlacht? | 287 | sharedeals.de | Neuer Zündstoff für unsere Volltreffer-Empfehlung Abivax: Die französische Zeitung La Lettre berichtet von Übernahmegesprächen zwischen dem Biotechunternehmen und dem US-Pharmariesen Eli Lilly. Spannend:... ► Artikel lesen | |
| 12:30 | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | 255 | Investor Magazin | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| 07:06 | GenSight Biologics S.A.: GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ in France | 243 | Business Wire |
French medicines agency ANSM has granted authorization for named patient early access program for GS010/LUMEVOQ, a gene therapy indicated for the treatment of ND4-LHON.
Regulatory News:
GenSight... ► Artikel lesen | |
| 07:06 | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025 | 194 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 08:26 | Faron Pharmaceuticals: Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer | 154 | ACCESS Newswire | Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients... ► Artikel lesen | |
| 12:39 | Regeneron Pharmaceuticals: Nach erfolgreichem Ausbruch - Pullback-Szenario bietet attraktives Setup! | 132 | ratgeberGELD.at | Chance nach charttechnischem Befreiungsschlag! Rückblick Seit Ende Oktober befindet sich die Regeneron-Aktie in einem stabilen Aufwärtstrend. Nach einem scharfen Rücksetzer hat sich der Kurs über der... ► Artikel lesen | |
| 12:51 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | 130 | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 12:06 | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Approval of EKTERLY (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | 128 | Business Wire | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY (sebetralstat)... ► Artikel lesen | |
| 08:06 | Alvotech announces European launch of first-in-market biosimilar to Simponi (golimumab) globally by partner Advanz Pharma | 127 | GlobeNewswire (Europe) | Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) - Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the... ► Artikel lesen | |
| So | Telix Pharmaceuticals Limited: Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions | 105 | GlobeNewswire (Europe) | MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation... ► Artikel lesen | |
| 13:06 | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | 30 | Business Wire | Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| AMGEN | 279,45 | 8,13 | +2,91 % | 2,52 | 13.02.2026 | |
| RECORDATI | 48,260 | 1,30 | +2,69 % | 0,63 | 24.11.2025 | |
| STRYKER | 300,80 | 2,90 | +0,96 % | 0,88 | 31.12.2025 | |
| BIO-TECHNE | 49,600 | 0,27 | +0,54 % | 0,08 | 17.11.2025 | |
| REGENERON PHARMACEUTICALS | 654,80 | 3,04 | +0,46 % | 0,88 | 20.11.2025 | |
| BIOGEN | 148,80 | 0,00 | 0,00 % | |||
| ENZO BIOCHEM | 0,388 | 0,00 | 0,00 % | |||
| MYRIAD GENETICS | 5,500 | 0,00 | 0,00 % | |||
| TRANSGENE | 0,928 | 0,00 | 0,00 % | |||
| INOVIO PHARMACEUTICALS | 1,900 | 0,00 | 0,00 % |